This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Peter Lutwyche, PhD
Chief Technology Officer at Genevant Sciences Corporation


Dr. Lutwyche has responsibility for manufacturing, process development, quality control, quality assurance and project management for all Arbutus product candidates as well as supporting Arbutus’s collaborative partners as they advance products based on Arbutus technology. Dr. Lutwyche joined Arbutus from QLT Inc., where he was employed for ten years, most recently as Director, Pharmaceutical Development. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of the product Visudyne as well as leading manufacturing and chemistry efforts for numerous preclinical and clinical stage products. Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.

Peter Lutwyche, PhD's Network

Agenda Sessions

  • The Design of Lipid Nanoparticles to Enable Delivery of Diverse Nucleic Acid Payloads Beyond the Hepatocyte